Press releases
- Actinium Presents First Ever Data Demonstrating Actimab-A in Combination with Leading Menin Inhibitors Leads to Anti-Tumor Control and Potent Leukemic Cell Killing in Preclinical Acute Myeloid Leukemia Models at the 2024 EHA Congress
- Actinium Highlights Oral Presentation at EHA 2024 Annual Congress Featuring Improved Outcomes in TP53 Positive Patients Receiving Iomab-B in the Phase 3 SIERRA Trial
- Actinium Announces Results of Actimab-A + CLAG-M Combination Trial Highlighted in Oral Presentation at the 2024 Society of Nuclear Medicine & Molecular Imaging Annual Meeting
- Actinium Highlights Mutation Data from the Phase 3 SIERRA Trial of Iomab-B and Novel Linker Technology to Support Solid Tumor Antibody Radiation Conjugate Development at the 2024 Society of Nuclear Medicine & Molecular Imaging Annual Meeting
- Actinium to Host KOL Webinar to Discuss Iomab-ACT Commercial CAR T-Cell Therapy Trial Design, Objectives and Potential Market Opportunity
- Actinium Announces Oral Presentation Detailing Improved Survival Outcomes in TP53 Positive Patients at the EHA 2024 Annual Congress and Presentation of Long-Term Efficacy Results in Older Patients Receiving an Iomab-B Led Bone Marrow Transplant in the Phase 3 SIERRA Trial
- Actinium Announces Multiple Abstracts Highlighting its Antibody Radiation Conjugates Iomab-B and Actimab-A and Novel Linker Technology for Solid Tumors Accepted for Presentation at the 2024 Society of Nuclear Medicine & Molecular Imaging Annual Meeting
- Actinium Announces KOL Webinar to Highlight Recently Announced Iomab-ACT Trial with Leading FDA Approved Commercial CAR T-Cell Therapy Being Led by the University of Texas Southwestern
- Actinium Highlights Ability of Iomab-B to Overcome High-Risk TP53 Mutation Resulting in Significant Improvement in Overall Survival in Patients with Active Relapsed Refractory AML at the European Bone Marrow Transplant Annual Meeting
More ▼
Key statistics
On Thursday, Actinium Pharmaceuticals Inc (7AY1:STU) closed at 6.58, -27.83% below its 52-week high of 9.11, set on May 15, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 6.58 |
---|---|
High | 6.58 |
Low | 6.58 |
Bid | 6.56 |
Offer | 6.86 |
Previous close | 6.34 |
Average volume | 84.89 |
---|---|
Shares outstanding | 29.78m |
Free float | 29.15m |
P/E (TTM) | -- |
Market cap | 216.82m USD |
EPS (TTM) | -1.72 USD |
Data delayed at least 15 minutes, as of Jul 04 2024.
More ▼